◼ Archived
Business
Verastem CEO claims RAS drug has 'set a new benchmark' for tricky cancer in early readout
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.
1 trends tracked about this subject — the full history, oldest to newest below.
Verastem advances its experimental KRAS inhibitor to Phase III following positive early data and a major funding round.